Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rupikang Pian is a traditional Chinese medicine (TCM) tablet developed by Shaanxi Momentum Pharmaceutical. It is formulated with a blend of herbal ingredients, including *Prunella vulgaris* (selfheal spike), *Citrus reticulata* leaf, *Salvia miltiorrhiza* (red sage), *Carthamus tinctorius* (safflower), *Curcuma aromatica* (wild turmeric), *Gleditsia sinensis* thorn, *Cyperus rotundus* (nut grass), and *Pheretima* (earthworm). Rupikang Pian is approved in China for the treatment of hyperplasia of the mammary gland (lobular hyperplasia of the breast) and breast distending pain, acting by soothing the liver, regulating qi, promoting blood circulation, and resolving stasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rupikang Pian.